Sanderling Venture Partners VI LP bought $326K of CalciMedica (CALC)
Executed Nov 1 2024, disclosed Nov 5 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 5 2024), the stock returned -13.8% (delay-adjusted); from the execution session (Nov 1 2024), -8.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Sanderling Venture Partners VI LP (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in CalciMedica, Inc. (CALC). Across 1 priced purchase filing, the average 21-session return was -8.5% from execution and -13.8% from disclosure (delay-adjusted; derived). The largest single filing was $326K of CALC (86,867 sh × $3.75, as filed), executed Nov 1 2024.
Healthcare · CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic p…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→